جستجوی مقالات مرتبط با کلیدواژه « helicobacter pylori infection » در نشریات گروه « پزشکی »

Despite the numerous articles discussing the relationship between diabetes mellitus type 2 (DMT2) and chronic Helicobacter pylori (H. pylori) infection the results have been inconsistent, necessitating further research. This study investigated the coexistence of Helicobacter pylori infection and DMT2.

We conducted a study in selected laboratories in Tehran, measuring the H.Pylori stool antigen (HpSA) in individuals referred by physicians for a glycosylated hemoglobin A1c (HbA1c) test.

Out of the 2500 patients who were referred to randomly selected laboratories, a total of 2025 (81%) patients had serum HbA1c levels above 6.5%. of 2025 patients with HbA1c levels above 6.5%, 1321 (52.84%) had HpSA in their stool. No significant gender difference was observed, with a mean age ± SD, 48.65 ± 7.55. HpSA was positive in 52.84% of the DM group, while in the non-DM group, HpSA was positive in 37.36% of cases. Fecal antigen titers are not related to gender (P = 0.274) but are related to age (r = 0.213, P=0.034).

Long-term infection with Helicobacter pylori may be significantly associated with elevated HgA1c.Testing for H. pylori infection, regular monitoring of blood sugar and HbA1c levels in high-risk people can prevent DMT2.

Helicobacter pylori (H. pylori) infection is strongly related to peptic ulcer disease, chronic gastritis, and gastric malignancies. Therefore, H. pylori eradication is necessary in these cases. This study was aimed to compare the efficacy of 14-day reverse hybrid therapy with standard 14-day concomitant regimen for H. pylori eradication in Iran.

Of the 317 patients with dyspepsia and H. pylori infection enrolled in the study, 153 and 164 patients were randomly assigned to reverse hybrid and concomitant groups, respectively. The reverse hybrid regimen containing pantoprazole, amoxicillin, clarithromycin, and metronidazole was taken every 12 hours in the first 7 days, however, Clarithromycin and Metronidazole were discontinued within the next 7 days. Patients in the concomitant group also received the same drugs for 14-day. Eradication confirmation tests were used 8 weeks after the end of treatments.

A crowd of 281 patients continued the trial until the end. H. pylori eradication rates based on intention to treat analysis were 71.2% (109/153) and 83.5% (137/164) in reverse hybrid and concomitant groups, respectively (P = 0.007). By the per-protocol analysis, rates of eradication were 85.8% (109/127) and 89% (137/154), respectively (P = 0.428). Severe side effects were few in both groups. More side effects were observed in concomitant group (p < 0.001), however, the severity of side effects was not statistically different between the two regimens (P = 0.314). Reverse hybrid regimen was better tolerated (98% vs. 91.5%, P= 0.009).

Both 14-day reverse hybrid and concomitant regimens have a fair response rate in Iran.

Helicobacter pylori is a gram-negative curved bacillus that assumes a significant role in colon cancer and children´s diseases. This study aimed to examine the association between H. pylori infection with colon cancer and children´s diseases in order to achieve a a comprehensive understanding of these associations and for future works.

Three main databases (i.e., Cochrane Central Register of Controlled Trials [CENTRAL], Scopus, and MEDLINE) were systematically searched by two reviewers from their inception date to 2022 in order to determine the association between the H. pylori infection with the colon cancer and children’s diseases.

The findings of two meta-analyses were similar regarding the positive association between the risks of colorectal neoplasm (pooled OR=0.18; 95% CI of 0.99–1.40; P>0.05) and colon neoplasia (pooled OR=0.41; 95% confidence interval 1.24–1.60; P=0.000). H. pylori was associated with an increased risk of colorectal adenoma, adenocarcinoma, and advanced adenoma. Also H. pylori infection was correlated with a high risk of iron deficiency anemia (IDA), otitis media with effusion (OME), HenochSchonlein purpura, and growth disorders in children.

In sum, the H. pylori infection may have been associated with an increased risk of colorectal cancer and children’s diseases.

Various ways of treating H.pylori infection are reported, such as triple-therapy and quadruple therapy for two weeks. Some side effects have been seen during these treatments, besides Helicobacter pylori becoming resistant to these antibiotics easily. According to some studies, there is a relationship between metformin and reduction in Helicobacter pylori infection. Thus, in this study, we determine the effects of metformin on Helicobacter pylori infection.

We performed this assessment in a randomized, case-controlled way in the diagnosis of Helicobacter pylori infected outpatients and inpatients. In both groups (case group and control group), patients took two tablets for a two-week period. In the case group, the patients were given two metformin tablets (each containing 500mg of metformin (extended release) and in the control group, they were given two placebo tablets (each containing 500mg of white flour). We took h.pylori Ag stool test and rapid urease test to confirm the presence of Helicobacter pylori infection.

In this study, at first all the patients had positive h.pylori Ag stool test or positive rapid urease test. At the end of this study, the results of h.pylori Ag stool*- test presented that Helicobacter pylori infection was negative in 82.7% of the case group patients and 76% of control group patients which illustrates suppression of Helicobacter pylori infection. However, comparing to the control group (P=0.36), this difference was not statistically remarkable.

According to these findings, it is stated that having metformin along with prescribed antibiotics can help decrease Helicobacter pylori infection.

Idiopathic nephrotic syndrome is one of the most common glomerular diseases, which may be secondary to infections or systemic diseases. The aim of this study was to evaluate the effect of Helicobacter pylori (H. pylori) eradication on childhood nephrotic syndrome. 

In this randomized controlled clinical trial study, 38 children with concomitant idiopathic nephrotic syndrome and H. pylori infection were divided into 2 equal groups; the intervention group received a cotreatment for both diseases and the control group received only nephrotic syndrome treatment. Patients were followed for 6 months. Data were analyzed using SPSS 21 software.  Chi square test, Fisher exact test, and student t test were used. P value <0.05 was considered statistically significant.

The mean interval time from treatment to the recovery of nephrotic syndrome was 48.36±14.48 days in the intervention group and 51.68± 17.32 days in control groups, which was shorter in the intervention group, but not statistically significant. The recurrence of nephrotic syndrome and the mean number of recurrences in the intervention group were lower than the control group, but were not statistically significant. The frequency of diarrhea in the intervention group was significantly higher than the control group (p=0.003).

In children with concomitant idiopathic nephrotic syndrome and H. pylori infection, the treatment of both diseases may accelerate the recovery and decrease the recurrence of nephrotic syndrome.

BACKGROUND:

 Dyspepsia is a common complaint among patients who refer to gastroenterology clinics. Studies have shown that there is a strong relationship between dyspepsia and Helicobacter pylori (HP) infection. We have investigated the prevalence of HP infection in patients with dyspepsia and its correlation with age and socioeconomic status (SES) of patients in Mazandaran province, northern Iran.

In this cross-sectional study, patients with dyspepsia who had undergone upper gastrointestinal endoscopy were enrolled. Diagnosis of HP infection was according to the results of rapid urease test (RUT), and Giemsa staining of pathology samples. A questionnaire including endoscopic findings, demographic data, and SES information was completed for each patient.

The mean age of the 614 patients was 45.8±5 years, and 60% of them were female. Most patients had normal endoscopy (56.1%), and gastric ulcer and erosion was the most common abnormal endoscopic finding (24.7%). The prevalence of HP infection in patients with dyspepsia was about 66.6%. HP infection was associated with a lower prevalence in people aged below 30 years and good SES.

The prevalence of HP infection in patients with dyspepsia was 66.6%. In addition, HP infection rate was lower in people under the age of 30 years and patients with good SES.

The aim of the current study was to compare the efficacy of quadruple therapy including levofloxacin and clarithromycin for Helicobacter pylori eradication.

This clinical trial study was conducted on 189 patients with H. pylori infection who underwent gastroscopy and stomach biopsy in Shahid Beheshti Hospital, Kashan, Iran. After classification of patients, one group was treated with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12 h), amoxicillin (1 g/12 h), and clarithromycin (500 mg/12 h) and other group with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12h), amoxicillin (1 g/12 h), and levofloxacin (500 mg/12 h) for 2 weeks. After the end of the antibiotic treatment, omeprazole therapy was continued for 4 weeks. Two weeks after discontinuation of omeprazole, fecal antigen test was performed for both the groups to confirm the eradication of H. pylori infection.

The success of H. pylori eradication in the levofloxacin and clarithromycin groups was observed in 78 (89.7%) and 71 (69.6%) patients, respectively (P < 0.01). A significant difference was also seen between the two groups in terms of side effects and its incidence (P < 0.01), so that the incidence of side effect types in the clarithromycin group was more than the levofloxacin group except muscular pain and fatigue (P < 0.01).

Levofloxacin‑based quadruple regimen therapy was superior to clarithromycin-based quadruple regimens regarding H. pylori eradication and side effects. Therefore, the levofloxacin‑based regimen can be considered as an effective treatment for the first‑line anti‑H. pylori therapy

Several conducted studies have reported a higher and more frequent Helicobacter pylori infection rate in type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the prevalence and its association between H. pylori infection and T2DM.

A case and control study was conducted based on 529 T2DM patients and 529 control. H. pylori was assessed by Serum anti-H. pylori immunoglobulin G (IgG) and IgA. Furthermore, patients were investigated for fasting blood glucose (FBG) levels, glycosylated hemoglobin (HbA1c), serum cholesterol, and other biochemistry parameters.

The findings showed a positive significantly higher antibody titer for H. pylori infection (IgA > 250) in diabetic patients (50.7%) compared to controls (38.2%) (P < 0.001). Similarly, H. pylori infection for IgG > 300 titer was higher in T2DM patients (73.5%) compared to controls 61.8%) (P < 0.001). Further, the mean values were statistically significant diabetes with H. pylori infection for IgG > 300 titer and IgA > 250 titer, regarding Vitamin D, HbA1C (P < 0.001), FBG, calcium, creatinine, total cholesterol, LHDL, triglyceride levels, uric acid, bilirubin, thyroid-stimulating hormone (TSH), and systolic and diastolic blood pressure. The diabetic patients showed higher prevalence rate of symptoms than controls included: hypertension (14.3%), vomiting (15.5%), muscular symptoms (35.2%), bloating/distension (13.2%), abdominal pain (17%), nausea (9.6%), anemia (17%), kidneys (20.8%), chronic bronchitis (14.7%), gastrointestinal (23.8%), and diarrhea (20.4%).

The current study revealed that H. pylori infections were significantly higher in diabetic patients compared to controls. Furthermore, T2DM patients infected with H. pylori positive reported a higher prevalence rate of symptoms than H. pylori negative.

To investigate the possibility that the eradication of H pylori infection is associated with a reduction in the risk of glaucoma.

Sixty-five successive patients with elevated intraocular pressure (IOP) or glaucoma were included in the study. Serum samples from all subjects were analyzed for the presence of H pylori- antibodies using ELISA. Forty patients with positive serologic test were included. Half of the patients enrolled into intervention group and the other half registered as control. Intervention arm was referred to the Gastroenterology Clinic for eradication of H pylori and evaluated for the effect of H pylori regimen eradication on IOP and glaucoma over 2 months of follow-up. The age-matched controls did not receive treatment. Urea breath test was applied to confirm eradication.

There was a significant (p=0.005) reduction in IOP after complete eradication in the intervention group.  This value was not significant in control patients (p=0.08). The mean IOP before treatment of glaucoma in the control group was 23.60±2.37 mmHg and after treatment with anti-glaucoma drugs was 14.25±1.48 mmHg on the onset of study, and 13.55±2.01 mmHg after follow up. The mean IOP before treatment of glaucoma in the intervention group was 24.55±3.6 mmHg and after treatment with anti-glaucoma drugs was 15.15±1.8 mmHg, and 14.3±1.6 mmHg after the eradication of H pylori with a drug regimen. However, after the treatment of glaucoma in all patients, the overall comparison of mean IOP differences showed no statistical difference (P=0.65).

H pylori eradication therapy may have a positive effect on the management of glaucoma.

Helicobacter pylori infection is one of the most common chronic bacterial infections in the world, especially in the developing countries. This bacterium is the cause of many diseases such as lymphoma, gastritis, peptic ulcers, and stomach cancer. According to recent reports, H. pylori infection can potentially increase the risk of colon cancer. The current study aimed at investigating the association of H. pylori infection and the risk of colorectal cancer and adenomatous polyps. The current study was conducted on 50 patients with colon cancer and adenomatous polyps as the case group and 100 subjects with no specific pathologies (i e, polyps, neoplasms, or inflammatory diseases) as the control group. Blood samples were collected from the patients in order to assess the presence of anti-Helicobacter pylori infection antibodies, and the serum titer levels of anti-Helicobacter pylori IgG and IgA antibodies were measured using indirect enzyme-linked immunosorbent assay (ELISA) and a kit procured by Pishtaz Teb Company (Iran). A total of 33 patients in the current study had adenomatous polyps and 17 had colon cancer. H. pylori infection (IgA >20 U/mL and IgG >10 U/mL) was significantly more prevalent in the patients with colon cancer and adenomatous polyps compared with the healthy controls (P= 0.003, P= 0.039, respectively). The obtained results suggested that H. pylori infection can be considered as a risk factor for colon cancer and adenomatous polyps.

Helicobacter pylori (H. pylori) infection is a major casual factor in any peptic diseases. Clarithromycin as one of the drugs recommended for the infection eradication regimen has shown different levels of resistance. The present study is comparing the effectiveness of clarithromycin- and gemifloxacin - based quadruple regimens in H. pylori eradication.
This was a prospective double blind randomized clinical trial on patients with clear indication of H. pylori eradication. The patients were randomly divided into two groups: “BPAC group” treated with bismuth subcitrate (240 mg), pantoprazole (20 mg), amoxicillin (1 gr), and clarithromycin (500 mg), all twice daily, and the “BPAG group” treated with bismuth subcitrate, pantoprazole, and amoxicillin with same doses as “BPAC group” and gemifloxacin (320 mg daily) all for 10 days. Three months after the end of therapy, 14C Urea breath test was performed to confirm the eradication. All the patients were assessed for compliance and drug side effects. Based on per protocol (PP) and intention-to-treat (ITT) methods, data were analyzed and a P value 0.05 was considered as statistically significant. This project has been registered in the Iranian registry of clinical trials (IRCT).
Three patients were excluded from the survey and finally, 179 patients (89 patients in BPAC group and 90 patients in BPAG group) including 71(39.66%) men with the mean age of 46.4±12.3 years completed the treatment period. The incidence of side effects between the two study groups did not differ significantly. The success rate of BPAC regimen eradication was remarkably greater than BPAG regimen (ITT analysis; 89% vs 77%, respectively; CI 95%: 1.072-5.507, P The results showed that gemifloxacin is not a good alternative for clarithromycin in H. pylori eradication regimens in our region.

Demographic transition and increasing elderly population in Iran can be associated with age related disorders such as dementia. Recently, Helicobacter pylori infection was considered as a risk factor for cognitive impairment..
This study aimed to examine this relationship between H. pylori infection and cognitive impairment in Iranian elderly..
This cross-sectional study was performed on elderly subjects initially enrolled in the Amirkola health and ageing project. Demographic information was collected using a questionnaire and all participants filled the mini-mental state examination (MMSE) questionnaire. The maximum MMSE score is 30 points. Scores of 25 to 30 out of 30 are considered normal 21 to 24 as mild, 10 to 20 as moderate and 20 ur/mL was considered positive..
The study was performed on 1514 individuals with an average age of 69.3 ± 7.4 years. Overall, 836 (55.2 %) of the participants were male. Furthermore, 68.7% of the participants had normal MMSE score and 75.7% were seropositive for H. pylori. The risk of cognitive disorder in H. pylori positive patients (29.8%) was lower than H. pylori positive patients (35.9%) (RR = 0.81, CI95% = 0.67 - 0.97). No significant correlation was detected between H. pylori antibody level and MMSE score (r = 0.039, P = 0.129)..
In our population of elderly individuals in northern Iran, H. pylori infection was not associated with cognitive impairment in this large population..

The optimal treatment is not possible yet for chronic prostatitis due to the unknown etiology of the diseases. We aimed to investigate the association of Helicobacter pylori infection with chronic prostatitis.
In this prospective case-control study that conducted in Imam Hospital Complex affiliated to Tehran University of Medical Sciences in Tehran, Iran from 2014 to 2015, patients with diagnosis of chronic prostatitis according to the criteria of National Institute of Health (NIH) were enrolled. Control group constituted of consecutive healthy patients.Blood samples were obtained for each patient and control and evaluated for serum levels of anti H. pylori IgG, A. Data analysis was carried out using SPSS, version 18. Values of P Mean ± SD age of patients was 59.5 ± 3.08 yr in the case group and 56.88 ± 3.20 yr in the control group with no significant difference (P>0.05). Mean ± SD levels of anti H. pylori IgG and IgA in the control group were 9.36 ± 7.45 U/ml and 6.25 ± 7.29 U/ml, respectively compared with 20.94 ± 16.98 U/ml and 18.63 ± 15.65 U/ml in the case group, respectively both of which revealed statistically significant (P Chronic prostatitis is associated with H. pylori infection. Both anti H. pylori IgG and IgA are increased in patients with chronic prostatitis. Therefore, treatment of HP infection could be effective in the prostatitis cure.

In iron deficiency anemia (IDA), serum ferritin level is decreased and total iron binding capacity (TIBC) is increased
In this study the relationship between H. pylori infection and iron deficiency anemia were studied.
This research was a cross-sectional study. TIBC and ferritin levels were measured in 133 patients, suspected to H. pylori infection, then serum levels of IgM and IgG antibody against H. pylori infection were measured
From 133 patients, 97 were females (72.93%) and 36 males (28.07%), 36 of them (23 women and 13 men) have a TIBC levels more than 400 ug/dL and ferritin levels were less than 12ng/dL. Twenty patients had IgG antibodies and 5 patients had IgM against H. pylori.
The results show the association between H. pylori infection and increased levels of TIBC and decreased serum ferritin.

Constant monitoring of Helicobacter pylori resistance is necessary for selection of the best treatment regimen for eradication of the resistant strains..
The aim of this study was to investigate diversity of resistance and minimum inhibitory concentration (MIC) of H. pylori strains against metronidazole in Tehran, Iran..
Patients and This cross-sectional study was performed among 96 patients, who had undergone gastric endoscopy at Imam Khomeini hospital in Tehran, during years 2013 to 2014. Helicobacter pylori isolates were obtained from gastric biopsy samples on selective culture media after characterization by conventional biochemical tests and polymerase chain reaction. Minimum inhibitory concentration of metronidazole was determined by the agar dilution method..
Helicobacter pylori infection was detected in 22 patients (22.92%). Identity of the isolates was confirmed by PCR using glmM primers. Chronic gastritis, duodenitis, intestinal metaplasia, dysplasia and cancer were detected among 70.1%, 6.25%, 1.04%, 1.4% and 10.41% of the patients, respectively. Smoking showed a negative relationship with H. pylori infection. The rate of antibiotic resistance was 81.8% (18/22) and MIC ranges of 8 to 512 μg/mL were detected. Furthermore, MIC50 and MIC90 were determined as 256 and 512 µg/mL, respectively..
In conclusion, these results suggested a need for a switch to second line therapy regimens for treatment of infected patients in the Iranian population..